Still on FDA's Table: IVDMIAs, Rx/Dx Co-development, 510(k) Process, Promotion of Research-Use Dx

Speaking at the Personalized Medicine World Conference this week, FDA's Elizabeth Mansfield acknowledged that "things are changing hugely" at the agency.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.